secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2025-04-25T23:59:59+00:00
Accession:  0001558370-25-005554
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Director Mark Stolper to leave board at 2025 annual meeting; board rebalanced
-----------------------------------------------------------------------------

- Mark D. Stolper notified Board he will not stand for re-election at 2025 annual meeting; departure not due to any disagreement.
- Stolper will serve until election of directors at 2025 Annual Meeting, then expected to consult through Dec 31, 2026.
- Board decreased authorized directors from 10 to 9, effective upon Stolper's departure.
- Rita A. Karachun reclassified from Class II to Class I; Michael Ryan from Class III to Class II to balance board classes.
- Board now has three Class I, four Class II, and three Class III directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837025005554/0001558370-25-005554-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837025005554/chrs-20250422x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-005554

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer